Treatment with a GPIIb/IIIa Antagonist Inhibits Thrombin Generation in Platelet Rich Plasma from Patients

I. M. L. W. Keularts, S. Béguin, C. de Zwaan1, H. C. Hemker

From the Department of Biochemistry, Cardiovascular Research Institute Maastricht, University Maastricht, and the 1Department of Cardiology, Academic Hospital, Maastricht, Maastricht, The Netherlands

Summary

Infusion of the GPIIb/IIIa-inhibitor MK383 inhibits thrombin generation in platelet rich plasma by interfering with the production of platelet procoagulant phospholipid exposure. The effect is similar to that of 0.2 U/ml of heparin. Heparin infusion, well known to inhibit thrombin generation by fostering antithrombin activity, inhibits the formation of platelet-derived procoagulant microparticles, probably by decreasing the formation of free thrombin, which, under our circumstances, is the main platelet activator.

Introduction

It is still generally accepted that anti-platelet and anti-coagulant action are entirely different modes of action of antithrombotic drugs. On the basis of the observation that in vitro an antibody that blocks GPIIb:IIIa receptor of platelets also inhibits thrombin generation in platelet rich plasma (PRP), it has been surmised, however, that interfering with this platelet function may owe its effect not only to inhibition of platelet aggregation but also to dampening of thrombin generation through inhibition of the exposure of procoagulant phospholipids by the platelets (1-3). To test this hypothesis in a clinical situation, we measured thrombin generation in PRP from patients receiving MK-383, a non-peptide antagonist of GPIIb:IIIa that mimics the RGD sequence in fibrinogen, that is highly selective for the GPIIb:IIIa receptor and that is active in the nM range (5).

In the course of a clinical trial, approved by the ethics commission of our hospital, in which patients, upon informed consent, received at random either heparin (a 5000 IU i.v. bolus followed by infusion of 1000 IU per h for 48 h) or MK-383 (a loading dose of 0.6 µg/kg/min over 30 min and 0.15 µg/kg/min over the next 47.5 h), we had the opportunity to study eight patients with unstable angina or non-Q-wave myocardial infarction, receiving one or the other drug.

Materials and Methods

The first blood sample was drawn not earlier than 3 h after the start of the infusion. More than 18 h, i.e. over 6 times the half-life of the drugs (5), after the infusion had stopped, a control sample was drawn. Platelet rich plasma (PRP) was obtained by centrifugation of freshly drawn citrate blood (1 volume trisodium citrate 0.129 M to 9 volumes of blood) at 2650 × g, 10 min at 15° C. Platelet poor plasma (PPP) was made by double centrifugation at 2900 × g, 10 min at 15° C. Platelets were counted with a Coulter Counter MD18 and PRP was adjusted to 300 platelets/nl with autologous PPP.

Thrombin generation curves in PRP were obtained by subsampling from recalcified PRP into a chromogenic substrate of thrombin (S2238) as described in detail earlier (6, 7). The endogenous thrombin potential (ETP) i.e. the area under the curve, was assessed from these experiments. After thrombin generation was over (t > 20 min), sera were collected on ice, centrifuged for 1 min at 10,000 × g and frozen for later analyses of platelet membrane-derived procoagulant activity (PMPA) and residual prothrombin. For the PMPA determination, 7.5 µl of serum was added to 142.5 µl Hepes buffer A, pH 7.35 containing 8 mM CaCl2, 7 nM bovine F Va, 0.3 nM F Xa and 2 µM bovine prothrombin. After 2 and 4 min incubation at 37° C, 10 µl of the reaction mixture was tested for thrombin activity in 4 mM S2238 in the same buffer (8).

For the residual prothrombin determination, the increase in thrombin-like amidolytic activity caused by the addition of 1 µM staphylococcalase to serum or 1:40 diluted PPP (in Heps buffer) was determined. The residual prothrombin in serum is expressed as % of that of the original plasma.

Results and Discussion

MK-383 significantly inhibits thrombin generation in PRP but not in PPP (Table 1, Fig 1). This shows that the action of the drug is due to a reduction of platelet derived procoagulant activity and not to an influence on the coagulation system. This is corroborated by the observation that ionomycin, a drug that induces platelet procoagulant activity, bypassing the physiological mechanisms (9), relieves the inhibition obtained by blocking GPIIb/IIIa (results not shown). The inhibition observed was reflected in prothrombin consumption and formation of microparticles in serum (Table 1).

<table>
<thead>
<tr>
<th>ETP - PRP (nM/min)</th>
<th>PMPA (arb. units)</th>
<th>Residual Prothrombin (% of plasma)</th>
<th>ETP - PPP (nM/min)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MK-383</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>During treatment</td>
<td>327 ± 36</td>
<td>88 ± 21</td>
<td>11 ± 3</td>
</tr>
<tr>
<td>After treatment</td>
<td>429 ± 27</td>
<td>149 ± 23</td>
<td>5 ± 1</td>
</tr>
<tr>
<td>% of initial</td>
<td>76 ± 2</td>
<td>59 ± 1</td>
<td></td>
</tr>
</tbody>
</table>

| **Heparin**        |                  |                             |                   |
| During treatment   | 38 ± 22          | 49 ± 45                     | 68 ± 16           | 71 ± 27 |
| After treatment    | 421 ± 9          | 162 ± 34                    | 8.6 ± 3           | 450 ± 22 |
| % of initial       | 8.9              | 39.2                        |                   | 15.7   |

Figures indicate mean ± SD, n=8. Significant differences during the treatment, as determined by the Wilcoxon signed rank test for paired data, are in bold type.
Fig. 1
Thrombin generation curves in platelet rich plasma during and after treatment.

□ Control: MK-383 infused patient 24 h after the end of drug infusion (the control curve of the heparin treated patient was not significantly different)
○ Patient during infusion of MK 383
× Patient during infusion of heparin

In heparin treatment, the reduction of thrombin generation is due to the increase of antithrombin activity and thus observed in PPP. Interestingly, the formation of procoagulant microparticles is also significantly reduced by heparin treatment (Table 1). We think that this is secondary to the strong inhibition of the main platelet activator i.e. thrombin. This observation shows that a GPIIb:IIIa antagonist acts as an anticoagulant in PRP, and therefore probably also in vivo. Its effect is approximately equal to that obtained with 0.2 U/ml unfractionated heparin added to normal PRP (7). On the other hand, the anticoagulant action of heparin interferes with the procoagulant function of platelets.

Our results stress the importance of the interaction between platelets and the coagulation system. Further support for this view can be obtained from the observation that aspirin reduces thrombin generation in blood (10). Also the fact that both oral anticoagulation (11) and heparin treatment (12), two essentially different modes of anticoagulation, reduce coronary reinfarction, is suggestive of a narrow link between thrombin generation and, largely platelet-mediated, arterial thrombosis.

The large majority of studies on the coagulation system are carried out in PPP; platelet adhesion and aggregation on the other hand are most often studied in anticoagulated blood. Our results show that the traditional distinction between anti-platelet and anti-coagulant therapy fades as soon as the integrated system of platelets and coagulation factors is studied. This may be a helpful insight for the development of new antithrombotics.

Acknowledgement

This study was supported by Program Grant 900-526-192 from the Dutch Organisation for Scientific Research (N.W.O.).

References


Received March 17, 1998 Accepted after revision May 12, 1998